Share on StockTwits

Cubist Pharmaceuticals (NASDAQ:CBST)‘s stock had its “positive” rating reiterated by equities research analysts at Aegis in a research note issued to investors on Monday.

Cubist Pharmaceuticals (NASDAQ:CBST) traded down 0.07% during mid-day trading on Monday, hitting $72.19. 356,707 shares of the company’s stock traded hands. Cubist Pharmaceuticals has a 1-year low of $48.23 and a 1-year high of $82.12. The stock’s 50-day moving average is $68.15 and its 200-day moving average is $70.45. The company’s market cap is $5.436 billion.

Cubist Pharmaceuticals (NASDAQ:CBST) last posted its quarterly earnings results on Tuesday, April 22nd. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by $0.03. The company had revenue of $261.20 million for the quarter, compared to the consensus estimate of $285.24 million. During the same quarter in the prior year, the company posted $0.34 earnings per share. The company’s quarterly revenue was up 13.6% on a year-over-year basis. On average, analysts predict that Cubist Pharmaceuticals will post $0.58 earnings per share for the current fiscal year.

CBST has been the subject of a number of other recent research reports. Analysts at Jefferies Group raised their price target on shares of Cubist Pharmaceuticals from $87.00 to $88.00 in a research note on Monday. Separately, analysts at Gabelli initiated coverage on shares of Cubist Pharmaceuticals in a research note on Friday. They set a “buy” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Cubist Pharmaceuticals in a research note on Thursday. They now have a $72.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $75.43.

Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.